In the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims

1. (currently amended) A compound of formula (I):



formula (I)

wherein **A** is 5-membered heteroaryl containing a nitrogen atom and optionally containing one or two further nitrogen atoms;

X is O, S, S(O), $S(O)_2$ or NR^{14};

m is 0, 1, 2 or 3;

Z is a group selected from $-NR^1R^2$, phosphonooxy, C_{3-6}cycloalkyl which C_{3-6}cycloalkyl is substituted by phosphonooxy or C_{1-4}alkyl substituted by phosphonooxy, and a 4- to 7-membered ring linked via a carbon atom containing a nitrogen atom and optionally containing a further nitrogen atom, which ring may be saturated, partially saturated or unsaturated wherein the ring is substituted on carbon or nitrogen by phosphonooxy or C_{1-4}alkyl substituted by phosphonooxy, and wherein the ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups;

$\mathbf{R^1}$ is a group selected from $-COR^8$, $-CONR^8R^9$ and C_{1-6}alkyl which C_{1-6}alkyl is substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

$\mathbf{R^2}$ is a group selected from hydrogen, $-COR^{10}$, $-CONR^{10}R^{11}$ and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups or $-S(O)_pR^{11}$ (where p is 0, 1 or 2) or phosphonooxy, or R^2 is a group selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

or $\mathbf{R^1}$ and $\mathbf{R^2}$ together with the nitrogen to which they are attached form a 4- to 7- membered ring optionally containing a further nitrogen atom which ring may be saturated, unsaturated or partially saturated wherein the ring is substituted on carbon or nitrogen by a group selected from phosphonooxy and C_{1-4}alkyl which C_{1-4}alkyl is substituted by phosphonooxy or $-NR^8R^9$, and where the ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups;

R^{3} is a grou[[o]]p selected from hydrogen, halo, cyano, nitro, C_{1-6}alkoxy, C_{1-6}alkyl, $-OR^{12}$, $-CHR^{12}R^{13}$, $-OC(O)R^{12}$, $-C(O)R^{12}$, $-NR^{12}C(O)R^{13}$, $-C(O)NR^{12}R^{13}$, $-NR^{12}SO_2R^{13}$ and $-NR^{12}R^{13}$;

R^{4} is hydrogen or a group selected from C_{1-4}alkyl, heteroaryl, heteroarylC_{1-4}alkyl, aryl and arylC_{1-4}alkyl which group is optionally substituted by 1, 2 or 3 ~~substitutents~~ substituents selected from halo, methyl, ethyl, cyclopropyl and ethynyl;

R^{5} is selected from hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

R^{6} and **R**^{7} are independently selected from hydrogen, halo, C_{1-4}alkyl, C_{3-6}cycloalkyl, hydroxy and C_{1-4}alkoxy;

R^{8} is C_{1-4}alkyl substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

R^{9} is selected from hydrogen and C_{1-4}alkyl;

R^{10} is selected from hydrogen and C_{1-4}alkyl (optionally substituted by halo, C_{1-4}alkoxy, $S(O)_q$ (where q is 0, 1 or 2) or phosphonooxy);

R^{11}, **R**^{12}, **R**^{13} and **R**^{14} are independently selected from hydrogen, C_{1-4}alkyl and heterocyclyl;

or a pharmaceutically acceptable salt thereof.

2. (original) A compound according to claim 1 wherein A is a group of formula (a), (b), (c), (d) or (e):



(a)



(b)



(c)



(d)



(e)

where * is the point of attachment to the X group of formula (I) and ** is the point of attachment to the (CR^6R^7) group of formula (I); or a pharmaceutically acceptable salt thereof.

3. (original) A compound according to claim 2 wherein A is a group of formula (a) as defined in claim 2; or a pharmaceutically acceptable salt thereof.

4. (currently amended) A compound[[s]] according to ~~any one of claims 1, 2 or 3~~ claim 1 wherein X is NH; or a pharmaceutically acceptable salt thereof.

5. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein Z is $-NR^1R^2$ or a 5- to 6-membered saturated ring linked via a carbon atom containing a nitrogen atom and optionally containing a further nitrogen atom, wherein the ring is substituted on carbon or nitrogen by phosphonooxy or C_{1-4}alkyl substituted by phosphonooxy; or a pharmaceutically acceptable salt thereof.

6. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein R^1 is C_{1-5}alkyl substituted by phosphonooxy and R^2 is a group selected from hydrogen and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, or R^2 is a group selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl; or a pharmaceutically acceptable salt thereof.

7. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein R^1 is 2-phosphonooxyethyl; or a pharmaceutically acceptable salt thereof.

8. (currently amended) A compound according to ~~any one of claims 1 to 5~~ claim 1 where Z is $-NR^1R^2$ and R^1 and R^2 together with the nitrogen to which they are attached form a piperidine, pyrrolidine or piperazine ring which is substituted by a group selected from phosphonooxy, phosphonooxymethyl, 2-phosphonooxyethyl, *N*-ethyl-*N*-(2-phosphonooxyethyl)aminomethyl and *N*-(2-phosphonooxyethyl)aminomethyl and where the ring is optionally further substituted by 1 or 2 methyl; or a pharmaceutically acceptable salt thereof.

9. (original) A compound according to claim 8 wherein R^1 and R^2 together with the nitrogen to which they are attached form 2-(phosphonooxymethyl)pyrrolidinyl; or a pharmaceutically acceptable salt thereof.

10. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein R^4 is 3-fluorophenyl, 3,5-difluorophenyl or 2,3-difluorophenyl; or a pharmaceutically acceptable salt thereof.

11. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein R^3 is C_{1-4}alkoxy, halo or hydrogen; or a pharmaceutically acceptable salt thereof.

12. (original) A compound selected from:
{1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]piperidin-4-yl}methyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate;
{(2*S*)-1-[3-({4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;
{(2*R*)-1-[3-({4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;
{(2*S*)-1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](propyl)amino]ethyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](isobutyl)amino]ethyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](isobutyl)amino]ethyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](propyl)amino]ethyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](isobutyl)amino]ethyl dihydrogen phosphate;
2-{(2,2-dimethylpropyl)[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]piperidin-3-yl dihydrogen phosphate;
{(2*R*)-1-[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](prop-2-yn-1-yl)amino]ethyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](isopropyl)amino]ethyl dihydrogen phosphate;

2-[[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](prop-2-yn-1-yl)amino]ethyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](2-methoxyethyl)amino]ethyl dihydrogen phosphate;
2-{[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
2-{(cyclobutylmethyl)[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl](3,3,3-trifluoropropyl)amino]ethyl dihydrogen phosphate;
2-{allyl[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
2-{cyclobutyl[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
2-{cyclopentyl[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
2-{cyclopropyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
2-{(cyclopropylmethyl)[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
2-{cyclobutyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
2-{4-[({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)methyl]piperidin-1-yl}ethyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](isopropyl)amino]ethyl dihydrogen phosphate;
3-{[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}-3-methylbutyl dihydrogen phosphate;
2-{(2*S*)-1-[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}ethyl dihydrogen phosphate;
{(2*R*)-1-[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](propyl)amino]ethyl dihydrogen phosphate;

2-[[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](butyl)amino]ethyl dihydrogen phosphate;
2-{cyclopentyl[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
{(2*S*)-1-[3-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;
{(2*S*)-1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;
2-{cyclopentyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate;
2-{[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}-2-methylpropyl dihydrogen phosphate;
2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](propyl)amino]ethyl dihydrogen phosphate;
{(2*R*)-1-[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;
3-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]propyl dihydrogen phosphate
2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl](2-methoxyethyl)amino]ethyl dihydrogen phosphate
2-[[4-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)butyl](propyl)amino]ethyl dihydrogen phosphate;
2-[[4-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)butyl](ethyl)amino]ethyl dihydrogen phosphate;
{(2*R*)-1-[4-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)butyl]pyrrolidin-2-yl}methyl dihydrogen phosphate;
2-[[4-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)butyl](methyl)amino]ethyl dihydrogen phosphate;
{(2*S*)-1-[4-({4-[(5-{2-[(2,3-difluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)butyl]pyrrolidin-2-yl}methyl dihydrogen phosphate; and
2-{ethyl[3-({6-fluoro-4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1*H*-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate;
or a pharmaceutically acceptable salt thereof.

13. (currently amended) A pharmaceutical composition comprising a compound according to ~~any one of the preceding claims~~ claim 1 in association with a pharmaceutically acceptable diluent or carrier.

14.-17. (cancelled)

18. (currently amended) A method of treating a human suffering from a disease in which the inhibition of one or more Aurora kinases is beneficial, comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound ~~as defined in~~ according to claim 1 or a pharmaceutically acceptable salt thereof.

19. (currently amended) A method of treating a human suffering from colorectal, breast, lung, prostate, pancreatic or bladder and renal cancer or leukemias or lymphomas, comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound ~~as deinined in~~ according to claim 1 or a pharmaceutically acceptable salt thereof.

20. (currently amended) A process for the preparation of a compound of formula (I) ~~as defined in~~ according to claim 1 or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (II) into a compound of formula (I) by phosphorylation of an appropriate hydroxy group:



formula (II)

where A, X, m, R^3, R^4, R^5, R^6, R^7 and R^9 are as defined for formula (I); and **Z'** is a group selected from $-NR^{1'}R^{2'}$, hydroxy, C_{3-6}cycloalkyl which C_{3-6}cycloalkyl is substituted by hydroxy or C_{1-4}alkyl substituted by hydroxy, and a 4- to 7-membered ring linked via a carbon atom containing a nitrogen atom and optionally containing a further nitrogen atom, which ring may be saturated, unsaturated or partially saturated wherein the ring is substituted on carbon or nitrogen by hydroxy or C_{1-4}alkyl substituted by hydroxy and wherein the ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups; **$R^{1'}$** is a group selected from $-COR^{8'}$, $-CONR^{8'}R^9$ and C_{1-6}alkyl which C_{1-6}alkyl is substituted by hydroxy and

optionally further substituted by 1 or 2 halo or methoxy groups; $\mathbf{R^{2'}}$ is a group selected from hydrogen, $-COR^{10}$, $-CONR^{10}R^{11}$ and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups or $-S(O)_pR^{11}$ (where p is 0, 1 or 2) or hydroxy, or R^2 is a group selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;
or $R^{1'}$ and $R^{2'}$ together with the nitrogen to which they are attached form a 4- to 7- membered ring optionally containing a further nitrogen atom which may be saturated, unsaturated or partially saturated wherein the ring is substituted on carbon or nitrogen by a group selected from hydroxy and C_{1-4}alkyl which C_{1-4}alkyl is substituted by hydroxy or $-NR^{8'}R^9$ and where the ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups; and where $\mathbf{R^{8'}}$ is C_{1-4}alkyl substituted by hydroxy and optionally further substituted by 1 or 2 halo or methoxy groups:
and thereafter if necessary:
i) converting a compound of formula (I) into another compound of formula (I); and/or
ii) removing any protecting groups; and/or
iii) forming a pharmaceutically acceptable salt thereof.

21. (new) The method according to claim 18 wherein Aurora kinase is Aurora-A kinase or Aurora-B kinase.

22. (new) A compound according to claim 1, wherein:
A is a group of formula (a), (b), (c), (d) or (e):



(a)



(b)



(c)



(d)



(e)

where * is the point of attachment to the X group of formula (I) and ** is the point of attachment to the (CR^6R^7) group of formula (I);

X is NH;

m is 0, 1, 2 or 3;

Z is $-NR^1R^2$ or a 5- to 6-membered saturated ring linked via a carbon atom containing a nitrogen atom and optionally containing a further nitrogen atom, which ring is substituted on carbon or nitrogen by phosphonooxy or C_{1-4}alkyl substituted by phosphonooxy;

R^1 is C_{1-5}alkyl substituted by phosphonooxy;

R^2 is selected from hydrogen and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups or R^2 is selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

or R^1 and R^2 together with the nitrogen to which they are attached form a saturated 5- to 6-membered ring optionally containing a further nitrogen atom wherein the ring is substituted on carbon or nitrogen by a group selected from phosphonooxy and C_{1-4}alkyl which C_{1-4}alkyl is substituted by phosphonooxy or $-NR^8R^9$, and where the ring is optionally further substituted on carbon or nitrogen by 1 or 2 C_{1-4}alkyl groups;

R^3 is C_{1-4}alkoxy, halo or hydrogen;

R^4 is phenyl optionally substituted by 1 or 2 of fluoro or chloro;

R^5 is hydrogen or methyl; and

R^6 and R^7 are independently hydrogen, fluoro, chloro or methyl;

or a pharmaceutically acceptable salt thereof.

23. (new) A compound according to claim 1, wherein:

A is a group of formula (a):



(a)

where * is the point of attachment to the X group of formula (I) and ** is the point of attachment to the (CR^6R^7) group of formula (I);

X is NH;

m is 1, 2 or 3;

Z is $-NR^1R^2$;

R^1 is C_{1-5}alkyl substituted by phosphonooxy;

R^2 is selected from hydrogen and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, or R^2 is selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

R^3 is C_{1-4}alkoxy, halo or hydrogen;

R^4 is phenyl optionally substituted by 1 or 2 of fluoro or chloro;

R^5 is hydrogen; and

R^6 and R^7 are each hydrogen;

or a pharmaceutically acceptable salt thereof.

24. (new) A compound according to claim 1 wherein:

A is a group of formula (a):



(a)

where * is the point of attachment to the X group of formula (I) and ** is the point of attachment to the (CR^6R^7) group of formula (I);

X is NH;

m is 1, 2 or 3;

Z is $-NR^1R^2$;

R^1 is C_{1-5}alkyl substituted by phosphonooxy;

R^2 is selected from hydrogen and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, or R^2 is selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

R^3 is hydrogen;

R^4 is phenyl optionally substituted by 1 or 2 of fluoro or chloro;

R^5 is hydrogen; and

R^6 and R^7 are each hydrogen;

or a pharmaceutically acceptable salt thereof.

25. (new) A pharmaceutical composition comprising a compound according to claim 12 in association with a pharmaceutically acceptable diluent or carrier.